Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins
Autore:
Gigler, A; Dorsch, S; Hemauer, A; Williams, C; Kim, S; Young, NS; Zolla-Pazner, S; Wolf, H; Gorny, MK; Modrow, S;
Indirizzi:
Univ Regensburg, Inst Med Mikrobiol & Hyg, D-95053 Regensburg, Germany Univ Regensburg Regensburg Germany D-95053 , D-95053 Regensburg, Germany NYU Med Ctr, Dept Pathol, New York, NY 10016 USA NYU Med Ctr New York NY USA 10016 tr, Dept Pathol, New York, NY 10016 USA NHLBI, Hematol Branch, Bethesda, MD 20892 USA NHLBI Bethesda MD USA 20892NHLBI, Hematol Branch, Bethesda, MD 20892 USA Vet Affairs Med Ctr, New York, NY 10010 USA Vet Affairs Med Ctr New York NY USA 10010 Med Ctr, New York, NY 10010 USA
Titolo Testata:
JOURNAL OF VIROLOGY
fascicolo: 3, volume: 73, anno: 1999,
pagine: 1974 - 1979
SICI:
0022-538X(199903)73:3<1974:GONHMA>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; IMMUNE-RESPONSE; NS-1 PROTEIN; INFECTION; GENOME; REGION; GENES; IDENTIFICATION; PERSISTENCE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
35
Recensione:
Indirizzi per estratti:
Indirizzo: Modrow, S Univ3Regensburg, Inst Med Mikrobiol & Hyg, Franz Josef Str Allee11, D-9505 Univ Regensburg Franz Josef Str Allee 11 Regensburg Germany D-95053
Citazione:
A. Gigler et al., "Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins", J VIROLOGY, 73(3), 1999, pp. 1974-1979

Abstract

Infections caused by human parvovirus B19 are known to be controlled mainly by neutralizing antibodies. To analyze the immune reaction against parvovirus B19 proteins, four cell lines secreting human immunoglobulin G monoclonal antibodies (MAbs) were generated from two healthy donors and one human immunodeficiency virus type I-seropositive individual with high serum titers against parvovirus. One MAb is specific for nonstructural protein NS1 (MAb 1424), two MAbs are specific for the unique region of minor capsid protein VP1 (MAbs 1418-1 and 1418-16), and one MAb is directed to major capsid protein VP2 (MAb 860-55D). Two MAbs, 1418-1 and 1418-16, which were generatedfrom the same individual have identity in the cDNA sequences encoding the variable domains, with the exception of four base pairs resulting in only one amino acid change in the light chain. The NS1- and VP1-specific MAbs interact with linear epitopes, whereas the recognized epitope in VP2 is conformational. The MAbs specific for the structural proteins display strong virus-neutralizing activity. The VP1- and VP2-specific MAbs have the capacity to neutralize 50% of infectious parvovirus B19 in vitro at 0.08 and 0.73 mu g/ml, respectively, demonstrating the importance of such antibodies in the clearance of B19 viremia. The NS1-specific MAb mediated weak neutralizing activity and required 47.7 mu g/ml for 50% neutralization. The human MAbs with potent neutralizing activity could be used for immunotherapy of chronically B19 virus-infected individuals and acutely infected pregnant women. Furthermore, the knowledge gained regarding epitopes which induce strongly neutralizing antibodies may be important for vaccine development.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 06:59:31